Copyright Reports & Markets. All rights reserved.

Global Lung Cancer Vaccine Market Growth 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Lung Cancer Vaccine Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Lung Cancer Vaccine by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Lung Cancer Vaccine by Country/Region, 2017, 2022 & 2028
  • 2.2 Lung Cancer Vaccine Segment by Type
    • 2.2.1 Subunit Vaccines
    • 2.2.2 Live Attenuated Vaccines
    • 2.2.3 Conjugate Vaccines
    • 2.2.4 Inactivated Vaccines
    • 2.2.5 Recombinant Vector Vaccines
  • 2.3 Lung Cancer Vaccine Sales by Type
    • 2.3.1 Global Lung Cancer Vaccine Sales Market Share by Type (2017-2022)
    • 2.3.2 Global Lung Cancer Vaccine Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global Lung Cancer Vaccine Sale Price by Type (2017-2022)
  • 2.4 Lung Cancer Vaccine Segment by Application
    • 2.4.1 Man
    • 2.4.2 Woman
  • 2.5 Lung Cancer Vaccine Sales by Application
    • 2.5.1 Global Lung Cancer Vaccine Sale Market Share by Application (2017-2022)
    • 2.5.2 Global Lung Cancer Vaccine Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global Lung Cancer Vaccine Sale Price by Application (2017-2022)

3 Global Lung Cancer Vaccine by Company

  • 3.1 Global Lung Cancer Vaccine Breakdown Data by Company
    • 3.1.1 Global Lung Cancer Vaccine Annual Sales by Company (2020-2022)
    • 3.1.2 Global Lung Cancer Vaccine Sales Market Share by Company (2020-2022)
  • 3.2 Global Lung Cancer Vaccine Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Lung Cancer Vaccine Revenue by Company (2020-2022)
    • 3.2.2 Global Lung Cancer Vaccine Revenue Market Share by Company (2020-2022)
  • 3.3 Global Lung Cancer Vaccine Sale Price by Company
  • 3.4 Key Manufacturers Lung Cancer Vaccine Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Lung Cancer Vaccine Product Location Distribution
    • 3.4.2 Players Lung Cancer Vaccine Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Lung Cancer Vaccine by Geographic Region

  • 4.1 World Historic Lung Cancer Vaccine Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Lung Cancer Vaccine Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Lung Cancer Vaccine Annual Revenue by Geographic Region
  • 4.2 World Historic Lung Cancer Vaccine Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Lung Cancer Vaccine Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Lung Cancer Vaccine Annual Revenue by Country/Region
  • 4.3 Americas Lung Cancer Vaccine Sales Growth
  • 4.4 APAC Lung Cancer Vaccine Sales Growth
  • 4.5 Europe Lung Cancer Vaccine Sales Growth
  • 4.6 Middle East & Africa Lung Cancer Vaccine Sales Growth

5 Americas

  • 5.1 Americas Lung Cancer Vaccine Sales by Country
    • 5.1.1 Americas Lung Cancer Vaccine Sales by Country (2017-2022)
    • 5.1.2 Americas Lung Cancer Vaccine Revenue by Country (2017-2022)
  • 5.2 Americas Lung Cancer Vaccine Sales by Type
  • 5.3 Americas Lung Cancer Vaccine Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Lung Cancer Vaccine Sales by Region
    • 6.1.1 APAC Lung Cancer Vaccine Sales by Region (2017-2022)
    • 6.1.2 APAC Lung Cancer Vaccine Revenue by Region (2017-2022)
  • 6.2 APAC Lung Cancer Vaccine Sales by Type
  • 6.3 APAC Lung Cancer Vaccine Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Lung Cancer Vaccine by Country
    • 7.1.1 Europe Lung Cancer Vaccine Sales by Country (2017-2022)
    • 7.1.2 Europe Lung Cancer Vaccine Revenue by Country (2017-2022)
  • 7.2 Europe Lung Cancer Vaccine Sales by Type
  • 7.3 Europe Lung Cancer Vaccine Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Lung Cancer Vaccine by Country
    • 8.1.1 Middle East & Africa Lung Cancer Vaccine Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Lung Cancer Vaccine Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Lung Cancer Vaccine Sales by Type
  • 8.3 Middle East & Africa Lung Cancer Vaccine Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Lung Cancer Vaccine
  • 10.3 Manufacturing Process Analysis of Lung Cancer Vaccine
  • 10.4 Industry Chain Structure of Lung Cancer Vaccine

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Lung Cancer Vaccine Distributors
  • 11.3 Lung Cancer Vaccine Customer

12 World Forecast Review for Lung Cancer Vaccine by Geographic Region

  • 12.1 Global Lung Cancer Vaccine Market Size Forecast by Region
    • 12.1.1 Global Lung Cancer Vaccine Forecast by Region (2023-2028)
    • 12.1.2 Global Lung Cancer Vaccine Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Lung Cancer Vaccine Forecast by Type
  • 12.7 Global Lung Cancer Vaccine Forecast by Application

13 Key Players Analysis

  • 13.1 GlaxoSmithKline
    • 13.1.1 GlaxoSmithKline Company Information
    • 13.1.2 GlaxoSmithKline Lung Cancer Vaccine Product Offered
    • 13.1.3 GlaxoSmithKline Lung Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 GlaxoSmithKline Main Business Overview
    • 13.1.5 GlaxoSmithKline Latest Developments
  • 13.2 Oncothyreon Incorporation
    • 13.2.1 Oncothyreon Incorporation Company Information
    • 13.2.2 Oncothyreon Incorporation Lung Cancer Vaccine Product Offered
    • 13.2.3 Oncothyreon Incorporation Lung Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 Oncothyreon Incorporation Main Business Overview
    • 13.2.5 Oncothyreon Incorporation Latest Developments
  • 13.3 Eli Lily
    • 13.3.1 Eli Lily Company Information
    • 13.3.2 Eli Lily Lung Cancer Vaccine Product Offered
    • 13.3.3 Eli Lily Lung Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 Eli Lily Main Business Overview
    • 13.3.5 Eli Lily Latest Developments
  • 13.4 ImClone Systems
    • 13.4.1 ImClone Systems Company Information
    • 13.4.2 ImClone Systems Lung Cancer Vaccine Product Offered
    • 13.4.3 ImClone Systems Lung Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 ImClone Systems Main Business Overview
    • 13.4.5 ImClone Systems Latest Developments
  • 13.5 Boehringer Ingelheim
    • 13.5.1 Boehringer Ingelheim Company Information
    • 13.5.2 Boehringer Ingelheim Lung Cancer Vaccine Product Offered
    • 13.5.3 Boehringer Ingelheim Lung Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 Boehringer Ingelheim Main Business Overview
    • 13.5.5 Boehringer Ingelheim Latest Developments
  • 13.6 Merck
    • 13.6.1 Merck Company Information
    • 13.6.2 Merck Lung Cancer Vaccine Product Offered
    • 13.6.3 Merck Lung Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Merck Main Business Overview
    • 13.6.5 Merck Latest Developments
  • 13.7 Ono Pharmaceutical
    • 13.7.1 Ono Pharmaceutical Company Information
    • 13.7.2 Ono Pharmaceutical Lung Cancer Vaccine Product Offered
    • 13.7.3 Ono Pharmaceutical Lung Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Ono Pharmaceutical Main Business Overview
    • 13.7.5 Ono Pharmaceutical Latest Developments
  • 13.8 CureVac
    • 13.8.1 CureVac Company Information
    • 13.8.2 CureVac Lung Cancer Vaccine Product Offered
    • 13.8.3 CureVac Lung Cancer Vaccine Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 CureVac Main Business Overview
    • 13.8.5 CureVac Latest Developments

14 Research Findings and Conclusion

The global market for Lung Cancer Vaccine is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Lung Cancer Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Lung Cancer Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Lung Cancer Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Lung Cancer Vaccine market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Lung Cancer Vaccine players cover GlaxoSmithKline, Oncothyreon Incorporation, Eli Lily, ImClone Systems and Boehringer Ingelheim, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Lung Cancer Vaccine market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Lung Cancer Vaccine market, with both quantitative and qualitative data, to help readers understand how the Lung Cancer Vaccine market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the Lung Cancer Vaccine market and forecasts the market size by Type (Subunit Vaccines, Live Attenuated Vaccines and Conjugate Vaccines), by Application (Man and Woman.), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Subunit Vaccines
Live Attenuated Vaccines
Conjugate Vaccines
Inactivated Vaccines
Recombinant Vector Vaccines

Segmentation by application
Man
Woman

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
GlaxoSmithKline
Oncothyreon Incorporation
Eli Lily
ImClone Systems
Boehringer Ingelheim
Merck
Ono Pharmaceutical
CureVac

Chapter Introduction
Chapter 1: Scope of Lung Cancer Vaccine, Research Methodology, etc.
Chapter 2: Executive Summary, global Lung Cancer Vaccine market size (sales and revenue) and CAGR, Lung Cancer Vaccine market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Lung Cancer Vaccine sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Lung Cancer Vaccine sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Lung Cancer Vaccine market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including GlaxoSmithKline, Oncothyreon Incorporation, Eli Lily, ImClone Systems, Boehringer Ingelheim, Merck, Ono Pharmaceutical and CureVac, etc.
Chapter 14: Research Findings and Conclusion
Buy now